CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DPRPS1K176NPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaDaunorubicin,Asparaginase,Methotrexate,CytarabineLi et al., 2015
DPRPS1D183EPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaDaunorubicin,Asparaginase,Methotrexate,CytarabineLi et al., 2015
DPRPS1A190TPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaDaunorubicin,Methotrexate,Cytarabine,AsparaginaseLi et al., 2015
DPRPS1T303SPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaCytarabine,Methotrexate,Daunorubicin,AsparaginaseLi et al., 2015
DPRPS1N144SPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMethotrexate,Asparaginase,DaunorubicinLi et al., 2015
DKRASR164QOncogenicDoes Not SupportOncogenicityCancerSmith et al., 2010
DKRASQ61HOncogenicSupportsOncogenicityCancerSmith et al., 2010
DFGFR3S249COncogenicSupportsOncogenicityLung Squamous Cell CarcinomaLiao et al., 2013
CBCR::ABL1Fusion AND ABL1 L364I AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 N146SPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 V289IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceAcute Lymphoblastic LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 S438CPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 M388LPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CFGFR3AmplificationPredictiveDoes Not SupportSensitivity/ResponseBreast CancerPazopanibWheler et al., 2016
CCHEK2R474C c.1420C>TPredisposingSupportsPredispositionCancerKukita et al., 2016
BCTNNB1Exon 3 MutationDiagnosticSupportsPositiveChildhood MedulloblastomaFattet et al., 2009
DPDGFRAOverexpressionPredictiveSupportsSensitivity/ResponseRhabdomyosarcomaSunitinibMcDermott et al., 2009
CBCR::PDGFRAFusionPredictiveSupportsSensitivity/ResponseB-cell Acute Lymphoblastic LeukemiaImatinibTrempat et al., 2003
CCOL1A1::PDGFBFusionPredictiveSupportsSensitivity/ResponseDermatofibrosarcoma ProtuberansSunitinibXiao et al., 2018
CPDGFRBOverexpressionPredictiveSupportsSensitivity/ResponseDermatofibrosarcoma ProtuberansSunitinibXiao et al., 2018
CETV6::NTRK3FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaLarotrectinibNardi et al., 2020
DETV6::NTRK3FusionPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaEntrectinibSmith et al., 2018
CSMU1::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CSNX29::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeLiu et al., 2016
CZNF430::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CTPM3::NTRK1FusionPredictiveSupportsSensitivity/ResponsePapillary Thyroid CarcinomaLarotrectinibRonsley et al., 2018
BSMARCA4INACTIVATING MUTATIONDiagnosticSupportsPositiveSmall-cell Carcinoma Of The Ovary Of Hypercalcemic TypeRamos et al., 2014
CBCR::ABL1Fusion AND ABL1 E355GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
CATF7IP::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CBCR::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CETV6::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CPPFIBP1::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CSSBP2::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2017
CPAX5::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeImamura et al., 2016
DPIK3CAE545KPredictiveSupportsResistanceCervical CancerCisplatin,Ionizing RadiotherapyArjumand et al., 2016
CRETM918T AND RET G810SPredictiveSupportsResistanceMedullary Thyroid CarcinomaSelpercatinibSolomon et al., 2020
CVHLSplice Site (c.340+1G>A)PredisposingN/AVon Hippel-Lindau DiseaseKreusel et al., 2000
CVHLQ132P (c.395A>C)PredisposingN/AVon Hippel-Lindau DiseaseKreusel et al., 2000
CVHLR161* (c.481C>T)PredisposingN/AVon Hippel-Lindau DiseaseKreusel et al., 2000
CEBF1::PDGFRBFusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeChemotherapy,ImatinibSakurai et al., 2021
BMYOD1L122RPrognosticSupportsPoor OutcomeSpindle Cell RhabdomyosarcomaTsai et al., 2019
DFGFR3R248CPredictiveDoes Not SupportResistanceCancerR3MabQing et al., 2009
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaFLT3/ABL/Aurora Kinase Inhibitor KW-2449Williams et al., 2013
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaSunitinibWilliams et al., 2013
DFLT3Y842CPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinWilliams et al., 2013
DFLT3F691LPredictiveSupportsResistanceAcute Myeloid LeukemiaLestaurtinibWilliams et al., 2013
DFLT3F691LPredictiveSupportsResistanceAcute Myeloid LeukemiaMidostaurinWilliams et al., 2013
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Akt Inhibitor MK2206Yang et al., 2012
Page 57 of 96
PreviousNext